Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2015 by Transition Therapeutics Ireland Limited
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Transition Therapeutics Ireland Limited
ClinicalTrials.gov Identifier:
NCT01735630
First received: November 25, 2012
Last updated: January 6, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)